Antiviral activity of recombinant mouse β-defensin 3 against influenza a virus in vitro and in vivo

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 6, 2012, Pages 255-262

  Jiang, Yan ^a,b   Yang, De ^c   Li, Wanyi ^b   Wang, Baoning ^b   Jiang, Zhonghua ^b   Li, Mingyuan ^b,d  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT BETA DEFENSIN 3; RECOMBINANT PROTEIN; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADSORPTION KINETICS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOG; DRUG INHIBITION; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LOW DRUG DOSE; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; UPREGULATION; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; BETA-DEFENSINS; CELL LINE, TUMOR; DOGS; GENE EXPRESSION REGULATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-12; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864824717     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2077     Document Type: Article

References (28)

1. Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In Knipe DM, Howley P, Griffin DE, Lamb RA, Martin MA (Editors). Fields Virology. 5th ed. New York: Lippincott Williams & Wilkins 2007; pp. 1692-1740.
2. World Health Organization. Influenza (seasonal). (Accessed 27 October 2009.) Available from http://www.who.int/mediacentre/factsheets/fs211/en/
3. Moss RB, Davey RT, Steigbigel RT, Fang F. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J Antimicrob Chemother 2010; 65:1086-1093.
4. Murphy AW, Plattes-Mills TAE, Lobo M, Hayden F. Respiratory nitric oxide levels in experimental human influenza. Chest 1998; 114:452-456.
5. Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/HongKong/ 156/97(H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998; 178:1592-1596.
6. Lowen AC, Mubareka S, Tumpey TM, et al. The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A 2006; 103:9988-9992.
7. Ottolini MG, Blanco JCG, Eichelberger MC, et al. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 2005; 86:2823-2830.
8. Zitzow LA, Rowe T, Morken T, et al. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002; 76:4420-4429.
9. Schneider JJ, Unholzer A, Schaller-Korting M, Korting HC. Human defensins. J Mol Med 2005; 83:587-595.
10. Seidel A, Ye Y, de Armas LR, et al. Cyclic and acyclic defensin inhibits human immunodeficiency virus type-1 replication by different mechanism. PLoS ONE 2010; 5:e9737.
11. Wang G, Watson KM, Buckheit RW. Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother 2008; 52:3438-3440.
12. Gong T, Jiang Y, Wang YL, et al. Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry. Arch Virol 2010; 155:491-498.
13. Liang QL, Zhou K, He HX. Retrocyclin 2: a new therapy against avian influenza H5N1 virus in vivo and vitro. Biotechnol Lett 2010; 32:387-392.
14. Smith JG, Silvestry M, Lindert S, et al. Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog 2010; 6:e1000959.
15. Wohlford-Lenane CL, Meyerholz DK, Perlman S, et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol 2009; 83:11385-11390.
16. Buck CB, Day PM, Thompson CD, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006; 103:1516-1521.
17. Hazrati E, Galen B, Lu W, et al. Human α-and β-defensins block multiple steps in Herpes Simplex Virus infection. J Immunol 2006; 177:8658-8666.
18. Akkarawongsa R, Potocky TB, English EP, et al. Inhibition of herpes simplex virus type 1 infection by cationic β-peptides. Antimicrob Agents Chemother 2008; 52:2120-2129.
19. Pazgier M, Hoover DM, Yang D, et al. Human β-defensins. Cell Mol Life Sci 2006; 63:1294-1313.
20. Jiang Y, Wang YL, Kuang Y, et al. Expression of mouse beta-defensin 3 in MDCK cells and its anti-influenza-virus activity. Arch Virol 2009; 154:639-647.
21. Jiang Y, Wang Y, Wang B, et al. Antifungal activity of recombinant mouse beta-defensin 3. Lett Appl Microbiol 2010; 50:468-473.
22. Reed LJ, Muench H. A simple method of estimating fifty percent end points. Am J Hyg 1938; 27:493-497.
23. Wilson BD, Sternick JL, Yoshizawa Y, et al. Experimental murine hypersensitivity pneumonitis: multigenic control and influence by genes within the I-B subregion of the H-2 complex. J Immunol 1982; 129:2160-2163.
24. Ganz T. Defensins: antimicrobial peptides of vertebrates. C R Biol 2004; 327:539-549.
25. Leikina E, Ayari HD, Melikov K, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005; 6:995-1001.
26. Yasin B, Wang W, Pang M, et al. θ defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78:5147-5156.
27. Monteiro JM, Harvey C, Trinchien G. Role of interleukin-12 in primary influenza virus infection. J Virol 1998; 72:4825-4831.
28. Niyonsaba F, Iwabuchi K, Matsuda H, et al. Epithelial cell-derived human β-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002; 14:421-426.